Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

BDRX vs NEXR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BDRX Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 7–0 Matrix Metrics)

BDRX Overall Winner 6-Pillar Tally: BDRX 3 – 1 NEXR (2 Tie) Matrix Metrics: BDRX 7 – 0 NEXR

As of Nov 16, 2026, Biodexa Pharmaceuticals plc American Depositary Shs (BDRX) is the stronger overall head-to-head candidate over NEXR (NEXR) in the Tradestie Institutional Equity Comparison Engine, winning 7–0 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BDRX carries a Unified Composite Score of 34.7/100 (SELL) at $2.35 (N/M Forward P/E, 0.0% operating margin), whereas NEXR carries 31.0/100 (SELL) at $1.38 (N/M Forward P/E, N/A operating margin).

  • Defensive Composite Rating Caution: Although BDRX compares more favorably head-to-head, both BDRX (34.7/100 SELL) and NEXR (31.0/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BDRX vs NEXR
BDRX NASDAQ Head-to-Head Winner
Biodexa Pharmaceuticals plc American Depositary Shs
Pharmaceutical Preparations
$2.35
-2.29% 1D
Market Cap $1.2M
TTM Revenue $83,000
Forward P/E N/M
Beta / 30D Vol 5.72β · 2679% Vol
Unified Composite Score
34.7 / 100 SELL
Tech 8.0 Fund 30.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (56.6% over 20 days), RSI 56
RSI-14: 55.6 · SMA20: $2.42 · SMA50: $1.38
NEXR US Equity
NEXR
Institutional Equity
$1.38
-7.38% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 8.42β · 2730% Vol
Unified Composite Score
31.0 / 100 SELL
Tech 50.0 Fund 27.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 54.5 · SMA20: $0.93 · SMA50: $1.16

6-Pillar Scorecard Institutional Category Breakdown (BDRX 3 – 1 NEXR)

Columns: Metric · BDRX · NEXR
1. Valuation Multiples BDRX
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 15.0x N/M
2. Growth & Scale BDRX
Revenue Growth (YoY) -64.1% N/A
Earnings Growth (YoY) +0.0% N/A
TTM Revenue (USD) $83,000 N/A
Market Cap $1.2M N/A
3. Profitability & Quality BDRX
Gross Margin N/A N/A
Operating Margin 0.0% N/A
Net Profit Margin 0.0% N/A
Return on Equity (ROE) -42.0% N/A
4. Balance Sheet & Cash Flow NEXR
Cash Generation (TTM) -$8.8M EBITDA N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $138.06 Book/Sh · -42.0% ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew Thin ADR Chain N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BDRX (7) vs NEXR (0)
Institutional Metric BDRX NEXR Criterion Row Edge
Market Capitalization
Scale
$1.2M N/A Larger Scale BDRX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-64.1% N/A Higher Growth BDRX
Operating Margin (TTM)
Profitability
0.0% N/A Higher Margin BDRX
Net Profit Margin
Profitability
0.0% N/A Higher Margin BDRX
Return on Equity (ROE)
Capital Efficiency
-42.0% N/A Higher ROE BDRX
52-Week Range Position
Momentum
23% ($0–$9) 23% ($0–$5) Stronger Trend Tie
Beta / 30D Volatility
Risk Regime
5.72β · 2679% Vol 8.42β · 2730% Vol Lower Realized Risk BDRX
Unified Institutional Score
Composite Signal
34.7 / 100 (SELL) 31.0 / 100 (SELL) Higher Composite BDRX
Trailing 12M Revenue (USD)
Operating Scale
$83,000 N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 15.0x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$8.8M EBITDA ($138.06 Book/Sh · -42.0% ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BDRX +346.87 pp
BDRX: +414.14% · NEXR: +67.27%
3M Horizon BDRX +116.44 pp
BDRX: +68.71% · NEXR: -47.73%
6M Horizon NEXR +26.29 pp
BDRX: -25.56% · NEXR: +0.73%
1Y Horizon BDRX +318.72 pp
BDRX: +279.51% · NEXR: -39.21%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BDRX vs NEXR. Trailing 12-month operating profitability (BDRX 0.0% vs NEXR N/A) and valuation multiples (BDRX N/M vs NEXR N/M Forward P/E) are benchmarked directly in Pillar 4 below.

BDRX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$83,000
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-42.0% · N/M
NEXR ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BDRX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BDRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NEXR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NEXR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BDRX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
NEXR Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BDRX vs NEXR Key Questions & Quantitative Answers

As of Nov 16, 2026, Biodexa Pharmaceuticals plc American Depositary Shs (BDRX) is the stronger overall head-to-head candidate over NEXR (NEXR) in the Tradestie Institutional Equity Comparison Engine, winning 7–0 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BDRX carries a Unified Composite Score of 34.7/100 (SELL) at $2.35 (N/M Forward P/E, 0.0% operating margin), whereas NEXR carries 31.0/100 (SELL) at $1.38 (N/M Forward P/E, N/A operating margin). Defensive Composite Rating Caution: Although BDRX compares more favorably head-to-head, both BDRX (34.7/100 SELL) and NEXR (31.0/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

BDRX leads the Growth & Scale pillar: BDRX posts -64.1% YoY revenue growth and +0.0% YoY earnings growth on $83,000 TTM revenue (N/A gross margin, 0.0% operating margin), compared with NEXR at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, BDRX generates $83,000 in USD-normalized revenue versus N/A for NEXR. In operating R&D and SG&A reinvestment, BDRX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NEXR.

BDRX screens cheaper on headline valuation multiples. BDRX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 15.0x EV/Revenue (unreported EBITDA margin), whereas NEXR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BDRX (-42.0% ROE) versus NEXR (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, BDRX carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (5.72β · 2679% Vol realized risk). By comparison, NEXR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (8.42β · 2730% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.